Browsing Cancer Biology by author "Hall, Emma"
Now showing items 1-16 of 16
-
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
Nutting, C; Morden, J; Bernstein, D; Beasley, M; Cosgrove, V; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
Clinical development of new drug-radiotherapy combinations.
Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; et al. (NATURE PUBLISHING GROUP, 2016-10-01)In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ... -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
Nutting, C; Morden, J; Beasley, M; Bhide, S; Emson, M; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar, I; Rooney, K; Roe, JWG; Patterson, JM; Bernstein, D; et al. (BMC, 2016-10-06)BACKGROUND: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of ... -
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; et al. (ELSEVIER SCIENCE INC, 2020-04-01)PURPOSE: The CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 Gy in 20 fractions over 4 weeks; and 57 Gy in 19 ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; et al. (ELSEVIER IRELAND LTD, 2020-03-01)BACKGROUND AND PURPOSE: The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ... -
Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition.
Brand, DH; Brüningk, SC; Wilkins, A; Naismith, O; Gao, A; et al. (ELSEVIER SCIENCE INC, 2023-12-01)PURPOSE: Rectal dose delivered during prostate radiation therapy is associated with gastrointestinal toxicity. Treatment plans are commonly optimized using rectal dose-volume constraints, often whole-rectum relative-volumes ... -
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins, A; Mossop, H; Syndikus, I; Khoo, V; Bloomfield, D; et al. (ELSEVIER SCIENCE INC, 2015-12-01)BACKGROUND: Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally ... -
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
Dearnaley, D; Griffin, CL; Silva, P; Wilkins, A; Stuttle, C; et al. (WILEY, 2023-07-18)OBJECTIVES: To compare the results of Gleason Grade Group (GGG) classification following central pathology review with previous local pathology assessment, and to examine the difference between using overall and worst GGG ... -
Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).
Harrington, K; Hall, E; Hawkins, M; Henry, A; MacKay, R; et al. (2017-11) -
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; et al. (ELSEVIER SCIENCE INC, 2018-06-01)PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ... -
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
de Mol van Otterloo, SR; Christodouleas, JP; Blezer, ELA; Akhiat, H; Brown, K; et al. (ELSEVIER SCIENCE INC, 2021-11-15)PURPOSE: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel ... -
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation.
Murray, J; Cruickshank, C; Bird, T; Bell, P; Braun, J; et al. (ELSEVIER IRELAND LTD, 2022-11-01)PEARLS is a multi-stage randomised controlled trial for prostate cancer patients with pelvic and/or para-aortic PSMA-avid lymph node disease at presentation. The aim of the trial is to determine whether extending the ... -
Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah, AB; Gulliford, SL; Morden, J; Newbold, KL; Bhide, SA; et al. (ELSEVIER SCIENCE LONDON, 2016-09-01)AIMS: To establish whether there is a difference in recovery of salivary function with bilateral superficial lobe parotid-sparing intensity-modulated radiotherapy (BSLPS-IMRT) versus contralateral parotid-sparing IMRT ... -
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
Nutting, CM; Morden, JP; Beasley, M; Bhide, S; Cook, A; et al. (ELSEVIER SCI LTD, 2018-11-01)PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the ...